Abstract
Stent thrombosis is a life-threatening sequela of drug-eluting stent implantation. Dual antiplatelet therapy with aspirin and thienopyridine is typically used to prevent this catastrophic event. In terms of stent thrombosis, the major concern is the variable response of patients to clopidogrel, and this has raised interest in new antiplatelet agents. We present the case of a 64-year-old woman whom we successfully treated with prasugrel after she had repeated episodes of stent thrombosis caused by a poor response to clopidogrel. This case highlights the potential role of new antiplatelet agents for patients who are undergoing drug-eluting stent implantation.
| Original language | English |
|---|---|
| Pages (from-to) | 483-486 |
| Number of pages | 4 |
| Journal | Texas Heart Institute Journal |
| Volume | 42 |
| Issue number | 5 |
| DOIs | |
| State | Published - 2015.10 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Clopidogrel
- Coronary disease/therapy
- Coronary restenosis/etiology/physiopathology/prevention and control
- Drug resistance
- Drug therapy/combination
- Drug-eluting stents/adverse effects
- Platelet aggregation inhibitors/therapeutic use
- Prasugrel
- Thrombosis/etiology/prevention and control
- Treatment outcome
Quacquarelli Symonds(QS) Subject Topics
- Medicine
Fingerprint
Dive into the research topics of 'Successful prasugrel therapy: For recurrent left main stent thrombosis in a clopidogrel hyporesponder'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver